Swedish biopharmaceutical group Ferring Pharmaceuticals has opened a state-of-the-art innovation center at Biopôle, adding a new hub for biologics research and development to the vibrant life sciences campus located in Lausanne, Switzerland.
The new Ferring Biologics Innovation Center targets unmet medical needs in the company’s specialist areas of reproductive medicine and maternal health, gastroenterology and uro-oncology. Ferring’s decision to invest in this cutting-edge infrastructure marks a leap forward in the company’s strategy to strengthen its capabilities and expertise in new biologic agents as it continues to grow.
Located in the heart of Western Switzerland’s Health Valley, Biopôle boasts a 2,000-strong community of industry leaders and academic experts, representing over a hundred of the world’s most innovative life sciences companies and research groups. As such, it offers Ferring privileged access to the technologies, expertise and talent it needs to power its new facility.
Founded in Malmö, Sweden, in 1950, Ferring Pharmaceuticals currently has approximately 6,500 employees in 56 countries, and markets its products to 110 countries. In 2006, the company established its global headquarters, a production facility, and an R&D center in Saint-Prex, between Lausanne and Geneva. The group employs 700 people on its Swiss site, covering administrative, technical, and scientific matters.
